CVR: 37541540
DKK 3,533,803
Gross profit
Net result: DKK 1,709,691
AmerisourceBergen International B.V.
CVR · view ownership and management
Director role ended: Laurent Maurice Robert Couston
CVR · 31/10/2024
View the full event history
Pharmalex Nordic ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Christopher Gauglitz and Åsa Pihlblad. The company is owned by AmerisourceBergen International B.V.. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 3,533,803 and a net result of DKK 1,709,691 compared with DKK -88,447,652 the year before. Equity in the 2025 report amounted to DKK -45,957,544.
Source: annual report 2025, Danish Business Authority
The financial health of Pharmalex Nordic ApS shows significant volatility, with a concerning decline in equity from 34.5 million DKK in 2022 to -45.9 million DKK in 2025. Gross profit has fluctuated, peaking at 4.08 million DKK in 2024 before dropping to 3.53 million DKK in 2025, while profitability turned negative in 2024 with a loss of 88.4 million DKK. The company's margins appear to be under pressure, and the negative equity position raises concerns about its long-term viability. Operating within the non-financial holding company sector, Pharmalex Nordic faces challenges in stabilizing its financial trajectory amidst these fluctuations.
AI-generated summary · Generated 15/08/2026
Selskabets formål er som holdingselskab at drive virksomhed med konsulentydelser inden for medicinalindustrien og anden hermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/10/2024 – 30/09/2025 | 3.5 mio. | 1.7 mio. | 202.9 mio. | -46 mio. | 2 | |
| 202401/10/2023 – 30/09/2024 | 4.1 mio. | -88.4 mio. | 195.4 mio. | -47.7 mio. | 2 | |
| 202201/01/2022 – 31/12/2022 | 3.3 mio. | 1.4 mio. | 276.3 mio. | 34.5 mio. | 2 | |
| 202101/01/2021 – 31/12/2021 | 3.4 mio. | 4.9 mio. | 58.9 mio. | 33.1 mio. | 2 | |
| 202001/01/2020 – 31/12/2020 | 2.6 mio. | 3.6 mio. | 58.7 mio. | 28.2 mio. | 2 | |
| 201901/01/2019 – 31/12/2019 | 2.4 mio. | 2.4 mio. | 59.9 mio. | 24.6 mio. | 2 | |
| 201801/01/2018 – 31/12/2018 | 1.9 mio. | 892 t. | 59.4 mio. | 22.2 mio. | 1 | |
| 201701/01/2017 – 31/12/2017 | 100 t. | 495 t. | 7.8 mio. | 2.9 mio. | 1 |
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorPharmalex Nordic ApS was founded on 16 March 2016.
Pharmalex Nordic ApS is registered under the industry Ikke-finansielle holdingselskaber (industry code 642120).
Pharmalex Nordic ApS had 1 employee in 2018 according to the Danish CVR register.
Pharmalex Nordic ApS is owned by AmerisourceBergen International B.V..
In 2025, Pharmalex Nordic ApS reported a gross profit of DKK 3,533,803.
The management of Pharmalex Nordic ApS consists of Christopher Gauglitz and Åsa Pihlblad.
Claim this page to add your logo and social links. Free to get started.
Pharmalex Nordic ApS has published its annual report for 2025. Gross profit came to DKK 3,533,803, and the net result was DKK 1,709,691.
Address changed to Lyngby Hovedgade 10C 10, 2800 Kongens Lyngby (February 3, 2026).
Pharmalex Nordic ApS has published its annual report for 2024. Gross profit came to DKK 4,083,048, and the net result was DKK -88,447,652.
As of October 31, 2024, Laurent Maurice Robert Couston has stepped down as director of Pharmalex Nordic ApS.
As of October 1, 2024, Åsa Pihlblad is registered as adm. dir. of Pharmalex Nordic ApS.
As of October 1, 2024, Torben Thers Nørgaard has stepped down as adm. dir. of Pharmalex Nordic ApS.
Pharmalex Nordic ApS has published its interim report for the period January 1, 2023 – September 30, 2023.
As of July 27, 2023, is registered as an owner of Pharmalex Nordic ApS with an ownership share of 100%.
Pharmalex Nordic ApS has published its annual report for 2022. Gross profit came to DKK 3,282,689, and the net result was DKK 1,404,916.
As of May 25, 2023, Laurent Maurice Robert Couston is registered as director of Pharmalex Nordic ApS.
As of May 25, 2023, Christopher Gauglitz is registered as director of Pharmalex Nordic ApS.
As of May 25, 2023, Dr. Raphael Troost has stepped down as director of Pharmalex Nordic ApS.
Pharmalex Nordic ApS has published its annual report for 2021. Gross profit came to DKK 3,352,246, and the net result was DKK 4,937,451.
Pharmalex Nordic ApS has published its annual report for 2020. Gross profit came to DKK 2,607,653, and the net result was DKK 3,603,867.
Pharmalex Nordic ApS has published its annual report for 2019. Gross profit came to DKK 2,373,391, and the net result was DKK 2,397,696.
Pharmalex Nordic ApS has published its annual report for 2018. Gross profit came to DKK 1,890,960, and the net result was DKK 891,680.
Pharmalex Nordic ApS has published its annual report for 2017. Gross profit came to DKK 99,661, and the net result was DKK 494,960.
As of March 5, 2018, Solveig Blomvik has stepped down as director of Pharmalex Nordic ApS.
As of February 21, 2018, Anette Langgaard Jacobsen has stepped down as director of Pharmalex Nordic ApS.
Pharmalex Nordic ApS has published its interim report for the period March 16, 2016 – December 31, 2016.
As of May 3, 2017, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Pharmalex Nordic ApS.
As of January 1, 2017, Torben Thers Nørgaard is registered as adm. dir. of Pharmalex Nordic ApS.
As of January 1, 2017, Dr. Raphael Troost is registered as director of Pharmalex Nordic ApS.
As of December 31, 2016, Dr. Raphael Troost has stepped down as adm. dir. of Pharmalex Nordic ApS.
As of July 5, 2016, Anette Langgaard Jacobsen is registered as director of Pharmalex Nordic ApS.
As of March 23, 2016, Solveig Blomvik is registered as director of Pharmalex Nordic ApS.
As of March 16, 2016, Dr. Raphael Troost is registered as adm. dir. of Pharmalex Nordic ApS.
Pharmalex Nordic ApS was founded on March 16, 2016.
Companies in the same industry and area
CVR 39074818
CVR 89462428
CVR 38654853
CVR 34079056
CVR 36700025
